In the last trading session, 1.13 million shares of the Candel Therapeutics Inc (NASDAQ:CADL) were traded, and its beta was -1.28. Most recently the company’s share price was $7.91, and it changed around -$1.07 or -11.87% from the last close, which brings the market valuation of the company to $351.80M. CADL currently trades at a discount to its 52-week high of $14.60, offering almost -84.58% off that amount. The share price’s 52-week low was $1.34, which indicates that the current value has risen by an impressive 83.06% since then.
Candel Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended CADL as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Candel Therapeutics Inc is expected to report earnings per share of -0.23 for the current quarter.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Instantly CADL has showed a red trend with a performance of -11.87% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 11.65 on recent trading dayincreased the stock’s daily price by 32.1%. The company’s shares are currently down -8.87% year-to-date, but still down -27.83% over the last five days. On the other hand, Candel Therapeutics Inc (NASDAQ:CADL) is 13.65% up in the 30-day period.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -46.75%. Candel Therapeutics Inc earnings are expected to increase by -4.53% in 2025, but the outlook is positive 0.88% per year for the next five years.
CADL Dividends
Candel Therapeutics Inc’s next quarterly earnings report is expected to be released in April.
BLACKROCK INC., with 2.819% or 0.82 million shares worth $5.1 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Select Portfolios – Biotechnology and iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 3.92 shares worth $30.97 million, making up 12.06% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 577.44 shares worth around $4.57 million, which represents about 1.78% of the total shares outstanding.
